BCG for treatment of NMIBC

Experts discuss the use of bacille Calmette-Guérin (BCG) as the standard treatment for high-risk non–muscle-invasive bladder cancer (NMIBC), when a patient is considered unresponsive to BCG, and how BCG shortages have impacted clinical practice and urologists in the community.

Video Player is loading.

Play Video

Play

Mute

Current Time 0:00

/

Duration 0:00

Loaded: 0%

Stream Type LIVE

Seek to live, currently behind liveLIVE

Remaining Time -0:00

 

1x

Playback Rate

Chapters

• Chapters

Descriptions

• descriptions off, selected

Captions

• captions settings, opens captions settings dialog
• captions off, selected

Audio Track

Fullscreen

This is a modal window.

The Video Cloud video was not found.

Error Code: VIDEO_CLOUD_ERR_VIDEO_NOT_FOUND

Session ID: 2025-05-31:996702b3644f54fed264f25d Player Element ID: vjs_video_915

OK

Close Modal Dialog

Beginning of dialog window. Escape will cancel and close the window.

Text

ColorWhiteBlackRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-Transparent

Background

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyOpaqueSemi-TransparentTransparent

Window

ColorBlackWhiteRedGreenBlueYellowMagentaCyanTransparencyTransparentSemi-TransparentOpaque

Font Size

50%75%100%125%150%175%200%300%400%

Text Edge Style

NoneRaisedDepressedUniformDropshadow

Font Family

Proportional Sans-SerifMonospace Sans-SerifProportional SerifMonospace SerifCasualScriptSmall Caps

Reset restore all settings to the default valuesDone

Close Modal Dialog

End of dialog window.

Close Modal Dialog

This is a modal window. This modal can be closed by pressing the Escape key or activating the close button.

EP: 1.Standard of Care and Intravesical Chemotherapy in NMIBC

Now Viewing

EP: 2.BCG for treatment of NMIBC

EP: 3.Cystectomy in NMIBC

EP: 4.New Intravesical Delivery Systems and TAR-200 in NMIBC

EP: 5.TAR-200 Efficacy and Safety in High-Risk BCG- Unresponsive NMIBC (SunRISe-1)

EP: 6.TAR-200 Clinical Development Program in NMIBC

EP: 7.Other Investigational Drug Delivery Systems in NMIBC

EP: 8.Cretostimogene Grenadenorepvec and Integration of Novel Therapies in High-Risk BCG-Unresponsive NMIBC

EP: 9.FDA-Approved Treatments for BCG-Unresponsive NMIBC

EP: 10.Use and Sequencing of Novel Treatments in NMIBC

EP: 11.Communication of Treatment Options for High-Risk NMIBC

EP: 12.Checkpoint Inhibitors for Treatment of NMIBC

EP: 13.Unmet Needs in NMIBC

EP: 14.Operationalizing TAR-200 and Other Delivery Systems in Practice

EP: 15.Patient Communication and Treatment Adherence in NMIBC

EP: 16.Uptake of New Treatments in Urology Practice

EP: 17.Final Thoughts and Clinical Trials in NMIBC

Video content above is prompted by the following:

• BCG has long been the standard treatment for high-risk NMIBC.
• When do you consider a patient to be unresponsive to BCG?
• How have BCG shortages impacted your practice/urologists in the community

Related Videos

NMIBC Treatment Decisions in the Age of BCG Shortages

Current Standards of Care and Shifting Strategies in NMIBC

Targeted Therapy in mHSPC: Effects of Mutation Absence

Real-World Outcomes With Nadofaragene in BCG-Unresponsive NMIBC

An Overview of Nogapendekin Alfa Inbakicept for High-Risk, BCG-Unresponsive NMIBC

Treatment Strategies for Symptomatic Bone Metastases in mHSPC

Interpreting PSA Trends in Patients Receiving Darolutamide Plus ADT With mHSPC

Ultra-Low PSA Threshold vs Traditional Thresholds In Clinical Practice

Adoption of New Treatment Modalities to Treat BPH

Safety data on Black patients from ARANOTE